Nadia Eckert Email & Phone Number

United States

Baltimore, Md, Us

Baltimore, Md, Us

In my current role, I lead a team of scientists developing innovative methods that utilize patient-derived induced pluripotent stem cells (iPSCs) as cellular models for investigating various neurological and neuroimmune disorders.

Brentford, Middlesex, Gb

- Led target identification and validation projects, collaborating with CROs, KOLs, industry partners, and academic institutions. - Advanced targets through pre-clinical pipeline for immune indications in collaborations with 23&me and the Broad Institute.- Initiated and developed experimental strategies for new targets in immune diseases by conducting CRISPR knockout and base editor screens in disease relevant cell types.- Supervised and trained laboratory staff. - Led GSK Health and Wellness programs in the Immunology Research Unit.

Brentford, Middlesex, Gb

- Led and coordinated a number of interinstitutional and interdepartmental projects, working globally with counterparts, stakeholders and matrix teams.- Developed and executed strategies for the use of CRISPR QTL and CRISPR KO screening in advanced cellular models (myeloid iPSCs) and their differentiated progeny. - Developed strategies/explored the biology and performed genetic analysis to identify genetically validated targets for metabolic and immune diseases.- Proposed, oversaw and coordinated functional genomics screens and target validation projects.- NextGen Sequencing (RNAseq, DNAseq, ChIPseq etc.), gene-editing (CRISPR KO, CRISPR HDR, etc.), Nanostring and other transcriptomics/genomics technical expertise.

Shanghai, Shanghai, Cn

• Project lead on assay development for a client’s gene therapy program: designed and tested adenoviral expression vectors (AAV2, AAV9), interacted with clients to address scientific design and project management, provided up to date results, and made changes and/or improvements for study design. * Designed and initiated projects for the development and/or improvement of cell-based and molecular assays in compliance with GMP standards. Created study protocols, batch records, client protocols, SOPs. • Transferred assays/assigned work to the operations testing group, trained and supervised staff to conduct custom and validated assays according to and in compliance with GLP/GMP, Code of Federal Regulations (CFR), and/or Points to Consider guidelines.• Served as a study director reviewing studies, generating reports and risk assessments.• Provided technical guidance, training, and managing technicians.

Philadelphia, Pa, Us

•Coordinated a successful cross-disciplinary group of biologists and chemists to discover small molecule compounds that reactivate Epstein-Barr virus (EBV) and intended to be used in combination with Ganciclovir as a targeted therapy to eliminate EBV-positive cancers.•Solid working knowledge of assay development, including the design and execution of in vitro and cell-based assays: developed several reporter cell-based assays to conduct a high-throughput screen to discover novel reactivators of EBV. •Validated and analyzed positive hits through in vitro and cell-based methods. Optimized the lead molecule for further development. •Designed and conducted experiments to identify the drug target. Performed microarray, proteomics (mass spec) and biological network analyses (IPA, KEGG, PINA, Oncomine) to define the drug target and mechanism-of-action. •Set up collaborations with medicinal chemistry/pharmacology experts at Drexel U COM Pharmacology Dept., UPENN Chemistry Dept. and multiple facilities at The Wistar Institute. •Developed a strategy to identify proteins that support or prevent EBV latency in B-cells by using a genome-wide RNAi screen. Identified a number of key cellular factors important for EBV intracellular maintenance and markers of EBV latency.

Philadelphia, Pa, Us

•Created animal models to study and characterize Cas family p130Cas and NEDD9 oncogenes’ function in cell motility, metastasis and tumor growth in Drosophila and mouse knockouts.•Characterized NEDD9-centered tumor signaling pathways/cell attachment signaling in mouse MMTV-driven mammary gland tumors.•Discovered and described the mechanism through which Cas oncogenes control cell surface adhesion through localization of E-cadherin/beta-catenin complex and induce metastasis. •Demonstrated synergy between Aurora kinase inhibitors and EGFR inhibitors Erlotinib or Cetuximab in a xenograft mouse model and by in vitro soft agar assay.•Conducted IHC and tumor tissue analysis to identify markers of metastasis/poor prognosis in patients with breast and ovarian carcinomas.•Published several first author and collaborative manuscripts, reviews on Cas oncogenes and a book chapter/tutorial on a dual bacterial/yeast two-hybrid technology and its use for building functional protein interaction networks.

Philadelphia, Pa, Us

•Developed a high-throughput yeast synthetic lethal screen for modulators of mitotic checkpoint proteins BUBR1 and BUB1•Characterized BUB1 domain structure and protein-protein interactions. Developed a yeast synthetic lethal assay and HTRF assay to screen for BUB1 protein interactors.•Identified and characterized Cdc6B, a novel developmentally-regulated isoform of a cell cycle replication initiation factor Cdc6.

Immunology Course

Ph.D., Cancer Biology, Biochemistry

Hmx Pro Immunology - Immuno-Oncology Course